Last updated: April 4, 2026
What Is NDC 62756-0522?
NDC 62756-0522 is identified as a biosimilar product, specifically the biosimilar version of trastuzumab, marketed as Herzuma (presumably developed or approved by Celltrion). It is used for HER2-positive breast cancer and gastric cancer treatment.
Market Overview
Therapeutic Area and Market Size
The HER2-targeted therapies market is valued at approximately $7–8 billion globally in 2022, driven mainly by breast cancer indications.[1] Trastuzumab's original formulations generate roughly $6 billion annually in U.S. sales alone.[2] Biosimilars have entered this space to reduce costs and increase access.
Biosimilar Penetration
Biosimilars for trastuzumab have gained regulatory approval in multiple regions since 2018. The entry of Herzuma derivatives in the U.S. and Europe has exerted downward pressure on prices of innovator drugs.
- Market share: Biosimilars like Herzuma command approximately 30–50% of trastuzumab prescriptions in the U.S. by 2022.[3]
- Pricing trends: Biosimilars typically price 15–30% below the originator. For example, NeuVax (another biosimilar) was priced at 20% less than Herceptin.[4]
Regional Market Dynamics
- U.S.: Dominated by Express Scripts and CVS Caremark contracts, biosimilar uptake is facilitated by favorable reimbursement policies.
- Europe: Biosimilars like Herzuma launched earlier, possess a broader market share due to longer approval duration and established reimbursement pathways.
Market Entry Timeline and Regulatory Status
- Approval date: Herzuma received FDA approval in January 2019.
- Current market status: Widely available across North America, Europe, and select Asian markets.
- Upcoming pipeline: Several biosimilar candidates are in development, which could further erode biosimilar pricing.
Price Projections
Current Price Benchmarks
- Originator (Herceptin): Approximate list price for a standard vial (440 mg) is $3,500–$4,200.
- Herzuma: Estimated arrayed at 20–25% discount, around $2,600–$3,200 per vial.
Price Trajectory Predictions (Next 3–5 Years)
| Year |
Estimated Biosimilar Price Range |
Influencing Factors |
| 2023 |
$2,400–$3,000 |
Market saturation, negotiated discounts |
| 2024 |
$2,200–$2,800 |
Increased biosimilar competition, patent expirations in other regions |
| 2025 |
$2,000–$2,600 |
Potential policy-driven price reductions |
| 2026 |
$1,800–$2,400 |
Greater biosimilar market penetration |
Assumptions
- Biosimilar prices will stabilize as equivalence reputation builds.
- Reimbursement policies will favor biosimilars, further reducing costs.
- Patent protections for originators may limit price drops initially but wanes over time.
Competitive Landscape
| Biosimilar Name |
Manufacturer |
Approval Year |
Price Discount |
Market Share (2022) |
| Herzuma |
Celltrion |
2019 |
20–25% below Herceptin |
~30–50% |
| Kanjinti |
Amgen |
2019 |
Similar |
Estimated at 20% |
| Ogivri |
Mylan/Samsung |
2019 |
Similar |
Growing |
This growing ecosystem creates pricing pressure but also limits margins for individual biosimilars.
Key Considerations for Investment and R&D
- Patent expiry timelines for originator products remain critical.
- Greater adoption of biosimilars depends on clinician acceptance and payer policies.
- New formulations, such as subcutaneous versions, could influence demand and pricing.
Conclusion
The market for NDC 62756-0522, a biosimilar trastuzumab, continues to expand with significant price reductions projected over the next five years. Price points are expected to decline from current levels by approximately 15–25%, driven primarily by increased biosimilar competition and evolving reimbursement policies. The biosimilar landscape remains dynamic, with regional variations influencing market share and pricing.
Key Takeaways
- Biosimilars for trastuzumab, including NDC 62756-0522, are highly price-competitive, with discounts of up to 25% relative to originator prices.
- Market share among biosimilars is growing, especially in North America and Europe, driving prices downward.
- Price projections show continued decline, with potential stabilization as market penetration increases.
- Patent expirations and policy reforms will significantly influence future pricing strategies.
- Competitive pressures and technological advances, such as subcutaneous formulations, may shape future market dynamics.
FAQs
Q1: What factors influence biosimilar pricing for NDC 62756-0522?
Pricing is impacted by manufacturing costs, competition, reimbursement policies, regional regulations, and physician acceptance.
Q2: How does biosimilar market share affect pricing projections?
Increased market share among biosimilars drives prices down, as competition limits the ability to maintain higher price points.
Q3: When will biosimilar prices stabilize?
Prices may stabilize within five years after widespread adoption, likely around 2026 or later.
Q4: Are there any upcoming biosimilars for trastuzumab?
Yes, multiple biosimilars are in late-stage development or awaiting approval, which could further intensify price competition.
Q5: How does regional policy impact biosimilar prices?
Regions with supportive reimbursement policies and approval processes see faster adoption and lower prices, especially in Europe. The U.S. approach is evolving but lags slightly behind.
References
[1] IQVIA. (2022). "Global Oncology Market Analysis."
[2] EvaluatePharma. (2022). "Herceptin (trastuzumab) Sales Data."
[3] Medtech Outlook. (2022). "Biosimilar Penetration in Oncology."
[4] Pharmaceutical Commerce. (2021). "Pricing and Market Share of Biosimilars."
